Posts Tagged ‘Cipla’

Select Pharma Stocks Gain On Tamiflu Demand :)

Pharma Stocks

As the Government is looking at ramping up procurement of the generic version of Tamiflu (oseltamivir), the share prices of those Indian pharma companies which might begin producing the drug, surged on Tuesday.

πŸ™‚

The share prices of these companies gained between two per cent and 19 per cent.

πŸ™‚

As the virus has reached pandemic levels with the death toll rising to fifteen and a large number of people having tested positive across the country, the Government is looking at stockpiling about another two crore capsules of the drug.

Tamiflu is currently being imported from Swiss drug maker, Roche.

πŸ™‚

Ranbaxy, Cipla, Natco Pharma, Strides Acrolabs and Panacea Biotech are vying to produce the generic version of the drug.

πŸ™‚

Strides closed up 4.78 per cent, Ranbaxy 6.71 per cent, Panacea Biotech 1.59 per cent and Natco Pharma 18.93 per cent.
Though Cipla closed the day down 0.48 per cent, it was up more than three per cent during the day.

πŸ™‚

Mr Jagannadham Thunuguntla, Equity Head at SMC Capital said that the Government looking at stocking up the drug immediately would boost the reputation of these companies.
β€œThis will not impact the bottomlines of these companies much.”

πŸ™‚

The Swine flu virus, which emerged in Mexico and the US first in April, has been spreading to other countries. 😦

It is a global pandemic which has hit India much later than other countries. Globally more than 1.6 lakh people have been affected and 1154 deaths have been recorded, according to the World Health Organisation.

πŸ™‚

The swine flu scare didn’t seem to affect the stock markets much as it ended the day flat; the Sensex closed up 64 points.

The BSE Health Care index was up 0.95 per cent, as 14 scrips advanced and 8 declined on Tuesday.

πŸ™‚

Corporate India, global cues push Sensex to 13-month high

Corporate India, global cues push Sensex to 13-month high

Corporate India provided a much needed boost to investors this week and buying interest at Indian equities markets resurfaced in the wake of a good set of earnings reports, pushing a key index to a 13-month high.

πŸ™‚

Other Asian markets also provided a prop to their Indian peers, with some key indices touching new highs.


The 30-share sensitive index ( Sensex) of the Bombay Stock Exchange (BSE) rose 291.35 points or 1.89 percent over previous Friday’s close and ended trade at 15,670.31 points.

This was its highest closing figure since June 17, 2008.

πŸ™‚

The broader S&P CNX Nifty of the National Stock Exchange (NSE) followed the Sensex, moving up 1.5 percent from its last weekly close to end at 4,636.45 points.

πŸ™‚

Lesser market capitalized scrips did better with the BSE’s midcap index closing 3.52 percent higher than its previous weekly close, while the BSE smallcap index was up 2.57 percent.

πŸ™‚


Data with markets watchdog Securities and Exchange Board of India (SEBI) showed that foreign funds were net buyers during the week, having bought scrips worth $735.7 million.


In July, foreign investors bought a total of $2.28 billion.

πŸ™‚

‘Positive results by corporates is proof that the economy is on the verge of a turnaround. This will continue to help the markets gain momentum,’ said Jagannadham Thunuguntla, equity head at SMC Capitals.

πŸ™‚

The Nifty, however, closed 0.08 percent higher at 4,572.3 points. πŸ™‚

The Reserve Bank of India (RBI) announced the first quarterly monetary policy review on Tuesday, but it turned out be a non-event for the markets with the central bank maintaining a status quo on key policy rates.


The week’s top gainers on the Sensex were Ambuja Cements (up 14.1 percent), Tata Motors (up 13.1 percent), Tata Power (up 11 percent), TCS (up 9.1 percent) and ITC (up 7.3 percent).


Among losers were Hero Honda (down 7.5 percent), Grasim (down 3.4 percent), Cipla (down 3.1 percent), Reliance Industries (down 3 percent), and Reliance Power (down 2.6 percent).